The negative prognostic value of TRAIL overexpression in oral squamous cell carcinomas does not preclude the potential therapeutic use of recombinant TRAIL. Invest New Drugs 2012;30(2):810-8.
. Four-miRNA Signature to Identify Asbestos-Related Lung Malignancies. Cancer Epidemiol Biomarkers Prev 2019;28(1):119-126.
. .